04Mar
Global Private Equity Newsletter - Winter 2020 Edition: Deals in the Life Sciences Sector Article 1: Value Drivers and Risks
As the private equity industry matures, and the deal landscape becomes more competitive, private equity sponsors are becoming more prepared and capable of investing in sectors previously considered overly-regulated, requiring advanced chemistry or...
By:
Dechert LLP
Related
Non-disclosure agreements (“NDAs”) can play a key component in encouraging American businesses to ...
Read More >
Our June 2019 article “discussed four new bills targeting equity, transparency, and discrimination...
Read More >
Joining the ranks of several other states and local jurisdictions that have taken similar steps in t...
Read More >
In today’s edition of Daily Compliance News: • Malaysia rejects $2bn settlement offer from Goldman...
Read More >
Corporate Governance and Securities Law Developments - Directors Can Be Held Liable for Failure to ...
Read More >
Taxpayers looking to utilize net operating losses (NOLs), excess interest carryovers and certain oth...
Read More >